Results 51 to 60 of about 44,133 (142)

Role of 5 alpha-reductase inhibitors in the management of prostate cancer

Clinical Interventions in Aging, 2006
Prostate cancer is one of the most complex and enigmatic oncologic problems in medicine. It is highly prevalent, particularly in elderly males. Unfortunately, its generally protracted and variable clinical course and high association with treatment-related morbidity raise serious questions about the ideal treatment strategy for the individual patient ...
Steven J, Hudak, Javier, Hernandez, Ian M, Thompson   +2 more
openaire   +2 more sources

Comparative Effectiveness and Safety of Finasteride and Dutasteride in the Treatment of Benign Prostatic Hyperplasia: A Real-World Retrospective Study

Medicina
Background and Objectives: Benign prostatic hyperplasia (BPH) is one of the most common chronic conditions in older men, significantly impairing quality of life (QoL) by causing lower urinary tract symptoms (LUTSs). 5-alpha-reductase inhibitors (5-ARIs),
Jarosław Ratajski, Kamil Ciechan, Paweł Jędrzejczyk, Tomasz W. Kaminski, Patryk Uciechowski, Tomasz Ząbkowski   +5 more
doaj   +1 more source

The efficacy of topical minoxidil 2% versus topical botanically derived inhibitors of 5 alpha reductase in treatment of female pattern hair loss by trichoscopy

Journal of the Egyptian Women’s Dermatologic Society, 2019
Background Female pattern hair loss (FPHL) is a distressing common problem. Minoxidil is the only FDA approved medical treatment for FPHL. However, the off-label botanically derived 5-alpha reductase inhibitors (5αRIs) are commonly used despite ...
Fairouz K Badran, Rania E Abd El Maksoud, Mona M Ibrahim Moawad   +2 more
doaj   +1 more source

Risks and side effects in the medical management of benign prostatic hyperplasia

Prostate International
Benign prostatic hyperplasia affects up to 80% of men in their lifetime. It causes bladder outflow obstruction, leading to lower urinary tract symptoms, which can have a large impact on quality of life.
Abdulghafour Halawani, Ryan Paterson, Tianshuang Zhong, Katie Du, Runhan Ren, Connor M. Forbes   +5 more
doaj   +1 more source

Major role for 5-alpha reductase inhibitors in the aging male

Canadian Urological Association Journal, 2012
The Canadian consensus meeting, held in Toronto in May 2006, represents an important initiative in sorting out much of the confusion surrounding the use of 5-alpha reductase inhibitors (5ARIs) in clinical practice. The impact of the Medical Therapy of Prostatic Symptoms study and the Prostate Cancer Prevention Trial (PCPT) are quite dramatic as they ...
openaire   +3 more sources

Diagnosis of prostate cancer with magnetic resonance imaging in men treated with 5-alpha-reductase inhibitors. [PDF]

World J Urol, 2023
Falagario UG, Lantz A, Jambor I, Busetto GM, Bettocchi C, Finati M, Ricapito A, Luzzago S, Ferro M, Musi G, Totaro A, Racioppi M, Carbonara U, Checcucci E, Manfredi M, D'Aietti D, Porcaro AB, Nordström T, Björnebo L, Oderda M, Soria F, Taimen P, Aronen HJ, Perez IM, Ettala O, Marchioni M, Simone G, Ferriero M, Brassetti A, Napolitano L, Carmignani L, Signorini C, Conti A, Ludovico G, Scarcia M, Trombetta C, Claps F, Traunero F, Montanari E, Boeri L, Maggi M, Del Giudice F, Bove P, Forte V, Ficarra V, Rossanese M, Mucciardi G, Pagliarulo V, Tafuri A, Mirone V, Schips L, Antonelli A, Gontero P, Cormio L, Sciarra A, Porpiglia F, Bassi P, Ditonno P, Boström PJ, Messina E, Panebianco V, De Cobelli O, Carrieri G, PROMOD Study Group.   +63 more
europepmc   +1 more source

Riboflavin, a testosterone 5.ALPHA.-reductase inhibitor.

The Journal of Antibiotics, 1990
O, Nakayama, M, Yagi, S, Kiyoto, M, Okuhara, M, Kohsaka   +4 more
openaire   +3 more sources

5-alpha-reductase inhibitors and risk of cardiovascular diseases

Urological Science, 2015
Teng-Fu Hsieh, Shang-Sen Lee, Tien-Huang Lin, Hsin-Ho Liu, Tsung-Hsun Tsai, Chi-Cheng Chen   +5 more
doaj   +1 more source

Effect of 5-alpha reductase inhibitors in animal models of Parkinson’s disease

Frontiers in Neuroendocrinology
Parkinson's disease (PD) is characterized by motor symptoms due to loss of brain dopamine and non-motor symptoms, including gastrointestinal disorders. Although there is no cure for PD, symptomatic treatments are available. L-Dopa is the gold standard PD therapy, but most patients develop dyskinesias (LID), which are challenging to manage.
Bourque, Mélanie, Morissette, Marc, Isenbrandt, Amandine, Giatti, Silvia, Cosimo Melcangi, Roberto, Carta, Manolo, Frau, Roberto, Bortolato, Marco, Soulet, Denis, Di Paolo, Thérèse   +9 more
openaire   +3 more sources

5-alpha-reductase inhibitors and risk of diabetes mellitus

Urological Science, 2016
Teng-Fu Hsieh, Shang-Sen Lee, Tien-Huang Lin, Hsin-Ho Liu, Tsung-Hsun Tsai, Chi-Cheng Chen   +5 more
doaj   +1 more source